Journal Scans
Carboplatin–Paclitaxel-Induced Leukopenia and Neuropathy Predict Progression-Free Survival in Recurrent Ovarian Cancer
Chemotherapy-Induced Leukopenia and Neuropathy Positive in Ovarian Cancer
CK Lee, H Gurney, C Brown, R Sorio, N Donadello, G Tulunay, W Meier, M Bacon, J Maenpaa, E Petru, N Reed, V Gebski, E Pujade-Lauraine, S Lord, RJ Simes, M Friedlander
20110626
2011 Jul 26
Br J Cancer
Carboplatin–Paclitaxel-Induced Leukopenia and Neuropathy Predict Progression-Free Survival in Recurrent Ovarian Cancer
Br J Cancer. 2011 Jul 26;105(3):360-365, CK Lee, H Gurney, C Brown, R Sorio, N Donadello, G Tulunay, W Meier, M Bacon, J Maenpaa, E Petru, N Reed, V Gebski, E Pujade-Lauraine, S Lord, RJ Simes, M Friedlander
TAKE-HOME MESSAGE
Abstract
Abstract
Background: We assess the prognostic value of chemotherapy-induced leukopenia and sensory neuropathy in the CALYPSO trial patients treated with carboplatin–paclitaxel (CP) or carboplatin–liposomal doxorubicin (CPLD).Methods: We performed a landmark analysis at first month after randomisation to correlate leukopenia (nadir white blood cell <4.0 × 109 per litre or severe infection) during cycle 1 of chemotherapy with progression-free survival (PFS). Using time-dependent proportional-hazards models,...
